Legacy Capital Partners Inc. trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 3.2% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 68,183 shares of the biopharmaceutical company’s stock after selling 2,265 shares during the period. Pfizer accounts for about 1.2% of Legacy Capital Partners Inc.’s holdings, making the stock its 28th largest holding. Legacy Capital Partners Inc.’s holdings in Pfizer were worth $2,474,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Steward Partners Investment Advisory LLC lifted its holdings in shares of Pfizer by 25.1% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 285,325 shares of the biopharmaceutical company’s stock valued at $10,352,000 after purchasing an additional 57,176 shares during the last quarter. Gagnon Securities LLC lifted its holdings in shares of Pfizer by 61.1% in the 1st quarter. Gagnon Securities LLC now owns 14,708 shares of the biopharmaceutical company’s stock valued at $522,000 after purchasing an additional 5,581 shares during the last quarter. Naples Global Advisors LLC lifted its holdings in shares of Pfizer by 5.4% in the 2nd quarter. Naples Global Advisors LLC now owns 33,695 shares of the biopharmaceutical company’s stock valued at $1,222,000 after purchasing an additional 1,712 shares during the last quarter. Pennsylvania Trust Co lifted its holdings in shares of Pfizer by 10.9% in the 2nd quarter. Pennsylvania Trust Co now owns 681,255 shares of the biopharmaceutical company’s stock valued at $28,127,000 after purchasing an additional 67,151 shares during the last quarter. Finally, Peapack Gladstone Financial Corp lifted its holdings in shares of Pfizer by 1.4% in the 1st quarter. Peapack Gladstone Financial Corp now owns 228,149 shares of the biopharmaceutical company’s stock valued at $8,097,000 after purchasing an additional 3,089 shares during the last quarter. 68.91% of the stock is owned by institutional investors.

Shares of PFE stock opened at $43.90 on Friday. The stock has a market capitalization of $260.68 billion, a P/E ratio of 16.57, a P/E/G ratio of 2.21 and a beta of 0.96. Pfizer Inc. has a 52-week low of $33.20 and a 52-week high of $44.46. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.91 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, July 31st. The biopharmaceutical company reported $0.81 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.07. The firm had revenue of $13.47 billion for the quarter, compared to analysts’ expectations of $13.30 billion. Pfizer had a return on equity of 25.35% and a net margin of 42.35%. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.67 EPS. equities research analysts forecast that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Monday, December 3rd. Investors of record on Friday, November 9th will be given a $0.34 dividend. This represents a $1.36 annualized dividend and a yield of 3.10%. Pfizer’s dividend payout ratio (DPR) is presently 51.32%.

In other Pfizer news, insider Sally Susman sold 40,381 shares of the business’s stock in a transaction that occurred on Friday, July 20th. The stock was sold at an average price of $37.22, for a total transaction of $1,502,980.82. Following the transaction, the insider now owns 155,377 shares in the company, valued at approximately $5,783,131.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Ian C. Read sold 486,753 shares of the business’s stock in a transaction that occurred on Monday, July 16th. The stock was sold at an average price of $37.36, for a total value of $18,185,092.08. Following the transaction, the chief executive officer now owns 1,145,693 shares in the company, valued at approximately $42,803,090.48. The disclosure for this sale can be found here. Insiders sold a total of 761,230 shares of company stock worth $29,054,690 in the last 90 days. 0.06% of the stock is currently owned by insiders.

Several research firms have recently weighed in on PFE. Morningstar set a $46.00 target price on Pfizer and gave the company a “buy” rating in a report on Thursday. Barclays reissued a “neutral” rating and issued a $40.00 target price on shares of Pfizer in a report on Wednesday. Cantor Fitzgerald set a $45.00 target price on Pfizer and gave the company a “buy” rating in a report on Wednesday. Morgan Stanley set a $45.00 target price on Pfizer and gave the company a “buy” rating in a report on Thursday, September 13th. Finally, JPMorgan Chase & Co. set a $42.00 target price on Pfizer and gave the company a “buy” rating in a report on Monday, September 10th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $41.89.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Read More: How is a Moving Average Calculated?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.